drugset / Trial / NCT00510484

Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

NCT00510484

Phase 3 Completed 35 enrolled Solvay Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will assess the effect of pancrelipase delayed release 24,000 unit capsules on fat and nitrogen absorption in subjects with PEI due to Cystic Fibrosis.

Timeline

Start
2007-11
Primary completion
2008-03
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Pancrelipase Protein / enzyme biologic 24000 iu

Indications